ADVM

About Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. is a clinical-phase biotechnology firm primarily engaged in discovering and advancing gene therapies. The company's mission is to create innovative treatments for various eye-related conditions and uncommon illnesses. Its flagship experimental gene therapy, ADVM-022, is a potential therapy administered through a single injection into the vitreous humor of the eye. This treatment is being developed for individuals afflicted with persistent retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies maintains licensing and collaborative partnerships with institutions such as the University of California and Cornell University, as well as companies like GenSight, Lexeo, and Virovek. Established in 2006, the organization was initially named Avalanche Biotechnologies, Inc. before rebranding to Adverum Biotechnologies, Inc. in May 2016. Its headquarters are situated in Redwood City, California.

CEO: Laurent Fischer
IPO Date: Jul 31, 2014

Market Data

Open: $4.24
High: $4.36
Low: $4.24
Volume: 676K
52W High: $6.07
52W Low: $1.78

Valuation

Market Cap: $96.3M
Enterprise Value: $159.1M

Financials

Free Cash Flow: -$92.9M
Revenue: $1M
Net Income: -$130.9M
Cash: $60.7M
Debt: $91.7M

Events

EarningsNov 12

EPS est. -1.8 · actual -2.03